(Q39728822)

14 September 2017

1 reference

title

Psychiatric disorders in parkinsonism. 1. Functional illnesses and personality (English)

1 reference

14 September 2017

1 reference

Harvey NS

1 reference

14 September 2017

language of work or name

1 reference

1 February 1986

1 reference

14 September 2017

1 reference

14 September 2017

1 reference

14 September 2017

1 reference

14 September 2017

page(s)

91-3, 97-8, 102-3

1 reference

Depressive symptoms in Parkinson patients referred for thalamotomy

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Psychiatric symptoms in Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Depression in Patients with Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Depression, intellectual impairment, and Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Is the mesocortical dopaminergic system involved in Parkinson disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

The Neurobiological Substrates of Depression in Parkinson’s Disease: A Hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Drugs and Reinforcement Mechanisms: A Critical Review of the Catecholamine Theory

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Cocaine-induced place preference conditioning: lack of effects of neuroleptics and 6-hydroxydopamine lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Cortical dopaminergic involvement in cocaine reinforcement

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Controlled study comparing nomifensine and clomipramine in unipolar depression, using the probenecid technique

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Psychiatric Side Effects of Levodopa in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Psychiatric aspects in Parkinsonism treated with L-dopa

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Does levodopa alter depression and psychopathology in Parkinsonism patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Deprenyl in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Release of [3H]dopamine byl-5-hydroxytryptophan

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Normalization of brain serotonin by L-tryptophan in levodopa-treated rats

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Mental symptoms in Parkinson's disease during chronic treatment with levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Affective disorder: studies with amine precursors

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Treatment with tryptophan of levodopa-associated psychiatric disturbances

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Tricyclic antidepressants as antimuscarinic drugs: in vivo and in vitro studies

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

IMIPRAMINE IN TREATMENT OF PARKINSONISM: A DOUBLE-BLIND PLACEBO STUDY

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Desipramine in treatment of Parkinson's disease. A placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Studies on brain metabolism of biogenic amines

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Nomifensine: effect in Parkinsonian patients not receiving levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Nomifensine in parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Parkinson's disease, depression, and ECT: a review and case study

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Parkinson's disease, depression, and electroconvulsive therapy: A clinical and neurobiologic synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Neuroendocrine evidence for increased responsiveness of dopamine receptors in humans following electroconvulsive therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Special antagonism of amphetamine-induced abnormal behaviour. Inhibition of stereotyped activity with increase of some normal activities

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Dopamine Nerve Terminals in the Rat Limbic Cortex: Aspects of the Dopamine Hypothesis of Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Levodopa-induced psychosis: a kindling phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Letter: Clozapine and agranulocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Clozapine and agranulocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Psychodynamics in parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Rorschach study on the nature and origin of common factors in the personalities of parkinsonians

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Cognitive deficits in the early stages of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

Twin study of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

1 reference

7 January 2021

The coincidence of schizophrenia and Parkinsonism: some neurochemical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2886%2972720-5

7 January 2021

10.1016/S0033-3182(86)72720-5

Identifiers

DOI

0 references

1 reference